Hellingman T, Kuiper BI, Buffart LM, et al. - In this observational cohort study, researchers sought to evaluate the potential survival benefit of repeat local treatment compared with systemic therapy in patients suffering from an early recurrence of colorectal cancer liver metastases (CRLM). Patients with recurrent CRLM within 12 months of initial local treatment with curative intent were identified retrospectively in Amsterdam University Medical Centers between 2009 and 2019. Using multivariable Cox regression analyses, differences in overall and progression-free survival among treatment strategies were assessed. In total, 135 patients were involved. Patients with CRLM who have a recent recurrence should be considered for repeat local treatment strategies. In patients with CRLM recurrence within 4 months of initial local treatment, a multimodality approach consisting of neoadjuvant systemic therapy followed by repeat local treatment appeared to be beneficial.